Stay updated on BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial

Sign up to get notified when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2 and removed Revision: v3.5.0.
    Difference
    0.1%
    Check dated 2026-04-19T13:40:14.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0. No visible changes to study content or page functionality.
    Difference
    0.1%
    Check dated 2026-03-21T17:37:17.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    The page footer now shows Revision: v3.4.3, replacing the previous Revision: v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-07T08:41:42.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    The footer revision tag was updated from v3.4.1 to v3.4.2.
    Difference
    0.1%
    Check dated 2026-02-13T17:45:10.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    Revision: v3.4.1 replaces the previous v3.4.0 on the page.
    Difference
    0.1%
    Check dated 2026-02-06T11:16:28.000Z thumbnail image
  8. Check
    89 days ago
    Change Detected
    Summary
    New UI options Show glossary and Hide glossary were added, and a revision note at the bottom now shows Revision: v3.4.0. The terms 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' were adjusted in wording/capitalization.
    Difference
    0.4%
    Check dated 2026-01-23T04:48:46.000Z thumbnail image

Stay in the know with updates to BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.